Hugel America

Hugel America is the U.S. subsidiary of Hugel, Inc., a leading global medical aesthetics company based in South Korea. The company focuses on the development and commercialization of botulinum toxin, hyaluronic acid fillers, and other aesthetic treatments. Its flagship product, Letybo (letibotulinumtoxinA-wlps), received FDA approval in 2024 for the treatment of moderate-to-severe glabellar lines. Hugel America aims to establish a significant presence in the North American aesthetics market by leveraging its parent company's manufacturing expertise and clinical data. The company's portfolio also includes the Croma-developed HA filler line, which it distributes in specific territories. Through strategic partnerships and a robust clinical pipeline, Hugel America is positioned as a key player in the evolving medical aesthetics landscape.